Table 4.

Engraftment data and clinical outcomes of treatment-naïve patients

No.	Age and sex	Neutrophil engraftment	Red cell engraftment	Platelet engraftment	Day 60 T cell	Day 60 PB	Day 360 T cell	Day 360 PB	Graft failure	aGVHD	cGVHD	CMV reactivation	EBV reactivation	Clonality PNH MK		Alive	Follow-up, mo
200 cGY TBI
1	16 M	19	16	21	100	100	77	95	No	No	No	No	No	—	46 XY	Yes	39
2	25 F	88	1		13	95			Primary	No	No	Yes	No	—	46 XX	No (D243)	8
3	11 F	17	27	27	100	100	100	100	No	No	No	No	No	—	46 XX	Yes	33
4	4 F	15	1	24	0	77			Secondary	No	No	No	Yes	—	46 XX	No (D121)	4
5	25 M	17	22	25	0	82			Secondary	No	No	Yes	No	—	46 XY	Yes	32
6	22 F	19	19	23	100	100			No	No	No	Yes	Yes	—	46 XX	Yes	30
7	23 F	22	39	30	100	100	77	99	No	No	No	Yes	No	—	46 XX	Yes	29
400 cGY TBI
8	17 M	15	16	16	100	100	100	100	No	No	No	No	No	—	46 XX	Yes	22
9	17 M	14	23	18	100	100	100	100	No	No	No	No	No	—	46 XY	Yes	22
10	63 F	16	18	29	100	100	100	100	No	Grade 2	No	No	No	—	46 XX	Yes	21
11	17 M	14	14	18	94	100	100	100	No	No	No	No	No	—	46 XY	Yes	19
12	26 M	15	24	20	99	100	100	100	No	No	No	No	No	—	46 XY	Yes	19
13	56 F	16	31	26	100	100	100	100	No	No	No	No	No	—	46 XX	Yes	17
14	51 M	16	372 (major ABO incompatible)	27	100	100	100	100	No	No	No	Yes	No	—	46 XY	Yes	16
15	20 M	24	43	39	100	100	NR	NR	No	No	No	Yes	No	—	46 XY	Yes	6
16	3 F	15	17	25	100	100	NR	NR	No	Grade 2	No	No	No	—	46 XX	Yes	5
17	52 M	20	24	32	100	100	NR	NR	No	No	No	Yes	No	—	46 XY	Yes	3

Neutrophil engraftment was defined as an ANC >1.0 × 10⁹/L measured for 3 consecutive measurements on different days. Red cell engraftment was counted as days from last packed RBC transfusion and platelet engraftment defined as a platelet count greater than 50 × 10³/μL for 7 days without transfusion. Chimerism was measured by PCR analysis of variable number of nucleotide tandem repeats unique to donors or recipients on total peripheral blood and isolated CD3⁺ T cells. Clonality was defined by presence of a PNH granulocyte clone >1% or a karyotypic abnormality. Patients were monitored for CMV reactivation by weekly measurement of CMV copy number by PCR of serum until day 60. Preemptive therapy with ganciclovir was initiated when ≥500 copies of CMV/mL serum were detected. Patients were also monitored for EBV reactivation by weekly measurement of EBV copy number by PCR of serum.